Why 2026 Is a Defining Year for Rheumatology Revenue Cycles
Rheumatology practices are operating in a billing environment more complex and higher-stakes than ever before. The 2026 Medicare Physician Fee Schedule (MPFS) carries yet another conversion factor adjustment. Biologic therapies continue to be the largest revenue driver and largest compliance target simultaneously. And the rise of AI-powered claim auditing means that even technically correct claims can be flagged for documentation gaps.
For rheumatologists, billing managers, and practice administrators, staying current on rheumatology CPT codes, ICD-10 pairings, modifier rules, and payer policies isn’t optional — it directly determines how much of every dollar of care you actually collect.
This guide is built for 2026. It covers every code category you encounter in a rheumatology practice, the MPFS updates that affect your fee schedules today, strategies the competition doesn’t discuss (biosimilar billing, care management codes, MIPS quality reporting), and a practical framework for reducing denials and surviving payer audits.
- Neolytix • Medical Billing
Medical Billing
Rheumatology CPT Codes: The Complete Reference
CPT (Current Procedural Terminology) codes, maintained by the American Medical Association, describe the services performed during a patient encounter. In rheumatology, three categories generate the vast majority of revenue: Evaluation & Management (E/M) visits, procedural codes (joint injections and aspirations), and drug administration codes for infusions and injections.
Evaluation & Management (E/M) Codes
E/M codes generate the largest share of revenue in most rheumatology practices. Since the AMA’s 2021 E/M guideline overhaul — refined further through 2026 — code level is determined by either medical decision-making (MDM) complexity or total time, whichever supports the higher level. This remains your single highest-yield billing improvement lever.
CPT Code | Description | 2026 Est. Medicare Rate |
99202 | New patient, straightforward MDM | ~$93.00 |
99203 | New patient, low complexity MDM | ~$134.00 |
99204 | New patient, moderate complexity MDM | ~$192.00 |
99205 | New patient, high complexity MDM | ~$261.00 |
99211 | Established patient, minimal | ~$24.00 |
99212 | Established patient, straightforward MDM | ~$57.00 |
99213 | Established patient, low complexity MDM | ~$98.00 |
99214 | Established patient, moderate complexity MDM | ~$133.50 |
99215 | Established patient, high complexity MDM | ~$178.00 |
99417 | Prolonged service add-on (per 15 min beyond 99215) | ~$36.00 |
MDM Complexity at a Glance for Rheumatology
MDM Level | Typical Rheumatology Visit Example |
Straightforward | Routine gout follow-up, no medication changes |
Low | Minor OA flare, single Rx renewal |
Moderate | RA patient with biologic management, labs reviewed, prior authorization needed |
High | New SLE diagnosis, multiple organ systems involved, specialist consult, new biologic initiation |
Time-Based Coding Thresholds (2026)
Code | Minimum Total Time on Date of Service |
99213 | 20 minutes |
99214 | 30 minutes |
99215 | 40 minutes |
99417 (add-on) | Each additional 15 minutes beyond 99215 threshold |
Pro Tip: For complex autoimmune patients requiring medication reviews, prior authorization discussions, lab interpretation, and care coordination, time-based coding frequently supports 99215 + 99417. Document total time including pre- and post-visit work performed on the date of service.
Procedural CPT Codes in Rheumatology
CPT Code | Description | 2026 Est. Medicare Rate |
20600 | Arthrocentesis, small joint (e.g., finger, toe) | ~$38.00 |
20604 | Arthrocentesis, small joint with ultrasound guidance | ~$95.00 |
20605 | Arthrocentesis, intermediate joint (e.g., wrist, ankle) | ~$43.00 |
20606 | Arthrocentesis, intermediate joint with ultrasound guidance | ~$105.00 |
20610 | Arthrocentesis, major joint (e.g., knee, shoulder, hip) | ~$59.20 |
20611 | Arthrocentesis, major joint with ultrasound guidance | ~$130.00 |
96372 | Subcutaneous/IM injection, therapeutic | ~$28.00 |
96401 | Chemotherapy injection, SC/IM (some biologics) | ~$97.00 |
J3301 | Triamcinolone acetonide injection (per 10 mg) | ASP-based |
Ultrasound-Guided Procedures: Codes 20604, 20606, and 20611 bundle imaging guidance into the procedure — do not separately bill ultrasound guidance code 76942 alongside these. Practices with ultrasound capability should actively track utilization of these higher-reimbursing codes.
ICD-10 Codes Every Rheumatologist Needs
Accurate, specific ICD-10 coding is the foundation of every paid claim. Payer edits are increasingly tied to code specificity — unspecified laterality, missing chronicity qualifiers, or outdated codes are among the most common denial triggers.
Common Rheumatology Diagnoses
ICD-10 Code | Description | Key Billing Note |
M05.70 | Seropositive RA with rheumatoid factor, unspecified site | Use site-specific codes whenever possible |
M05.761 | RA with effusion, right knee | Preferred over M05.70 for knee injections |
M06.9 | Rheumatoid arthritis, unspecified | Use for seronegative RA when site unspecified |
M32.10 | SLE, organ involvement unspecified | Acceptable for new/complex visits |
M32.14 | SLE with glomerular disease | Use when renal involvement documented |
M10.9 | Gout, unspecified | Use M10.00–M10.07 for site-specific gout |
M10.361 | Gout due to impairment of renal function, right knee | Specificity preferred by CMS |
M45.9 | Ankylosing spondylitis, site unspecified |
|
L40.50 | Psoriatic arthritis, unspecified |
|
L40.52 | Psoriatic arthritis mutilans |
|
M34.0 | Progressive systemic sclerosis |
|
M35.00 | Sjögren’s syndrome, unspecified |
|
M33.20 | Polymyositis, unspecified |
|
M31.6 | Other giant cell arteritis (GCA) | Critical for tocilizumab infusions |
M13.0 | Polyarthritis, not elsewhere classified |
|
Z-Codes and Supporting Diagnoses
ICD-10 Code | Description | When to Use |
Z79.899 | Long-term use of other medication | Every biologic/DMARD follow-up visit |
Z79.4 | Long-term use of insulin | Relevant when corticosteroid-induced diabetes is managed |
Z87.39 | Personal history of musculoskeletal disease | Surveillance visits |
Z00.00 | General adult medical exam | Wellness visits (if applicable) |
Documentation Rule: Always code to the highest specificity documented in the chart. “RA” alone is insufficient — specify seropositivity, affected sites, and any associated complications (effusion, deformity, vasculitis) when documented.
Modifier Mastery for Rheumatology Billing
Modifiers are among the most audited elements in rheumatology claims. Knowing precisely when to apply — and when not to apply — each modifier is essential for both maximum reimbursement and audit protection.
Modifier | Meaning | Rheumatology Use Case |
-25 | Significant, separately identifiable E/M on the same day as a procedure | 99214 billed same day as 20610 joint injection |
-59 | Distinct procedural service | Two injections at anatomically separate sites |
-76 | Repeat procedure by same provider | Repeat infusion on same service date |
-95 | Synchronous telehealth via audio/video | Virtual E/M visits |
-GQ | Asynchronous telehealth | Store-and-forward services (limited applicability) |
JW | Drug waste from single-use vial | Biologic where partial vial is discarded |
JZ | No drug waste from single-use vial | Required when entire vial is administered |
-GC | Service performed under resident’s care | Teaching facility supervision |
-AI | Principal physician of record | Hospitalist or attending distinction |
Modifier -25 in Practice: This is the single most-audited modifier in rheumatology. The OIG has consistently identified modifier -25 misuse across all specialties. To survive audit, the E/M note must stand completely independently from the procedure note — it must document a complaint, history, exam, and plan that are distinct from and medically necessary beyond the procedure being performed.
Biologic & Infusion Therapy Billing
Biologic infusion therapy is simultaneously the highest-revenue service line and the highest audit-risk area in rheumatology. Getting the coding right — every time — requires systematic documentation protocols.
Drug Administration CPT Codes
CPT Code | Description | 2026 Est. Medicare Rate |
96365 | IV infusion, initial substance, first hour | ~$78.40 |
96366 | IV infusion, each additional hour | ~$23.50 |
96367 | IV infusion, additional sequential substance, first hour | ~$62.80 |
96368 | IV infusion, concurrent | ~$23.00 |
96413 | Chemotherapy IV infusion, initial up to 1 hour | ~$138.00 |
96415 | Chemotherapy IV infusion, each additional hour | ~$32.50 |
96401 | Chemotherapy injection, SC or IM | ~$97.00 |
96372 | Therapeutic/prophylactic/diagnostic injection, SC/IM | ~$28.00 |
96365 vs. 96413: Use 96413/96415 for Rituximab and other agents classified as chemotherapy. Use 96365/96366 for non-chemotherapy biologics like Abatacept, Tocilizumab, and Belimumab. Misclassification is a common and costly error.
Common Biologic J-Codes (HCPCS)
Drug (Brand) | HCPCS Code | Unit | Primary Indications |
Rituximab (Rituxan) | J9312 | per 10 mg | RA, SLE, vasculitis |
Infliximab (Remicade) | J1745 | per 10 mg | RA, PsA, AS |
Abatacept (Orencia) | J0129 | per 10 mg | RA |
Tocilizumab (Actemra) | J3262 | per 4 mg | RA, GCA, SJIA |
Sarilumab (Kevzara) | J2182 | per mg | RA |
Belimumab (Benlysta IV) | J0490 | per 10 mg | SLE |
Ixekizumab (Taltz) | J2329 | per mg | PsA, AS |
Secukinumab (Cosentyx) | J3111 | per mg | PsA, AS |
Guselkumab (Tremfya) | J1890 | per mg | PsA |
JW and JZ Modifier Rules for Biologic Claims
As of the CMS rule effective January 1, 2023 (now fully enforced through 2026 audits), both JW and JZ are mandatory on every single-use drug claim. There is no scenario where neither modifier applies.
- JZ Modifier (No Drug Waste): Required when the entire contents of a single-dose vial are administered. Failure to append JZ is among the top biologic claim denial reasons.
- JW Modifier (Drug Waste): When a portion of a single-use vial is discarded, bill the administered amount under the primary HCPCS code and the wasted amount on a separate line with the JW modifier. Both amounts together must equal the full vial size.
Infusion Documentation Requirements (Non-Negotiable):
- Infusion start time and stop time (exact, not approximate)
- Drug name, dose, route of administration
- Lot number and expiration date
- Patient tolerance and any adverse events
- Supervising physician attestation (for incident-to claims)
- Pre-medication administration (if applicable — separately billable)
Biosimilar Billing: An Expanding Revenue Consideration
Biosimilars represent one of the most significant shifts in rheumatology billing over the past three years — and one that most billing guides under-address. With multiple biosimilars now approved for infliximab, rituximab, and adalimumab, practices face new coding decisions and payer policy variations.
Reference Biologic | Biosimilar Examples | HCPCS Code |
Infliximab (Remicade) | Inflectra, Renflexis, Avsola, Ixifi | Q5103, Q5104, Q5121, Q5119 |
Rituximab (Rituxan) | Truxima, Ruxience, Riabni | Q5115, Q5119, Q5123 |
Adalimumab (Humira) | Hadlima, Hyrimoz, Simlandi, others | Q5101, Q5120, etc. |
- Medicare reimburses biosimilars at ASP + 6% of the reference product’s ASP. Verify current CMS biosimilar reimbursement policy before billing as this may be subject to change.
- Always bill the specific HCPCS Q-code for the biosimilar dispensed — do not default to the originator’s J-code.
- Document the specific drug name and NDC number on the claim.
- Private payers vary significantly on biosimilar formulary placement. Some mandate biosimilar-first policies; others still require step therapy through originators.
Laboratory Testing Billing in Rheumatology
Lab testing is a significant revenue and documentation touchpoint in rheumatology. Many practices under-bill for labs ordered and performed in-office, and fail to link lab results to the visit note — weakening MDM documentation and E/M level support.
CPT Code | Test | Notes |
85025 | CBC with differential | Standard monitoring for DMARDs |
80053 | Comprehensive metabolic panel (CMP) | DMARD/biologic safety monitoring |
86200 | Anti-CCP antibody | RA diagnosis |
86038 | ANA (antinuclear antibody) | SLE, undifferentiated CTD |
86235 | Anti-dsDNA antibody | SLE monitoring |
86146 | Anti-beta-2 glycoprotein I | APS diagnosis |
86147 | Anticardiolipin antibody | APS diagnosis |
86431 | Rheumatoid factor | RA diagnosis/monitoring |
85651 | Erythrocyte sedimentation rate (ESR) | Inflammation monitoring |
86140 | C-reactive protein (CRP) | Inflammation monitoring |
86664 | Complement C3 | SLE activity monitoring |
86665 | Complement C4 | SLE activity monitoring |
83020 | Hemoglobin electrophoresis | Some anemia workups |
86812 | HLA typing, class I | AS, PsA diagnosis support |
36415 | Routine venipuncture | Bill once per encounter |
Lab and E/M Linkage: When you review lab results during a visit and those results inform your medical decision-making, explicitly document this in the visit note (e.g., “Reviewed CBC from [date]: WBC 4.2, no cytopenias; continuing methotrexate at current dose”). This converts lab review from a background activity into a documentable MDM element supporting higher E/M levels.
2026 Updates: What Changed in the Medicare Physician Fee Schedule
This section covers changes specific to the 2026 plan year. If you are visiting this guide for the first time and need the fundamentals, the sections above cover CPT codes, ICD-10, modifiers, and billing workflows in full.
2026 MPFS Conversion Factor and Key Rate Changes
The 2026 MPFS conversion factor is $32.35, a modest adjustment from 2025’s $32.19. While the change appears minor, the compounding effect across high-volume codes — particularly E/M visits and biologic infusions — meaningfully impacts annual revenue.
Change | 2025 Rate | 2026 Rate | Impact |
Conversion Factor | $32.19 | $32.35 | +$0.16/RVU |
99214 (Est. patient, mod. complexity) | $132.32 | $133.50 (est.) | Slight increase |
96365 (IV infusion, initial hour) | $77.12 | $78.40 (est.) | Slight increase |
20610 (Arthrocentesis, major joint) | $58.45 | $59.20 (est.) | Slight increase |
Prolonged Services (99417) | Revised | Continues | Time-based add-on |
Note: Actual 2026 Medicare rates vary by locality. Always verify current rates using the CMS Physician Fee Schedule Lookup Tool for your specific geographic practice location.
Other 2026 Policy Changes Affecting Rheumatology
Biologic Administration: Infusion administration codes (96365–96368, 96413–96415) received modest increases reflecting ongoing drug administration cost adjustments. The ASP + 6% reimbursement formula for Part B drugs remains in effect, though actual reimbursement lands near ASP + 4.3% after sequestration.
Telehealth Extensions: CMS has extended most telehealth flexibilities through at least the end of 2026. Rheumatology practices offering virtual care for established patients can continue billing telehealth E/M codes at parity with in-person rates for most payors.
JZ Modifier Enforcement: The CMS JZ modifier rule (effective January 1, 2023) is now a standard audit trigger. Any biologic drug claim without either JW or JZ will be automatically flagged by payer systems.
Prior Authorization: Your Most Valuable Non-Billable Workflow
- Document Step Therapy Failure: Most payers require proof that the patient has tried and failed at least two conventional DMARDs (typically methotrexate and hydroxychloroquine). Document these trials with start/stop dates, doses, and reasons for discontinuation.
- Match ICD-10 to Clinical Criteria: Ensure your diagnosis codes align precisely with the approved indication on the PA request. Payer clinical criteria for biologics are tied to specific ICD-10 codes.
- Attach Lab and Functional Data: RF titers, anti-CCP levels, DAS28 scores, HAQ scores, and imaging findings support medical necessity. Include these with every PA submission.
- Track PA Timelines: Most commercial payers respond to urgent PA requests within 72 hours and standard requests within 3–5 business days. Create a tickler system for PA renewals (typically annual for most biologics).
- Appeal Site-of-Care Directives Proactively: Many payers redirect infusions from physician offices to hospital outpatient departments (HOPDs) or specialty infusion centers. Document clinical necessity for in-office infusion — monitoring requirements, adverse event history, patient stability — to support appeals.
Telehealth & Remote Patient Monitoring in Rheumatology
Telehealth Billing
CMS has extended telehealth flexibilities for established patients through 2026. Rheumatology is exceptionally well-suited to telehealth — medication checks, lab reviews, patient-reported outcome assessments, and care management discussions can all be conducted virtually.
Service | CPT/HCPCS | Place of Service | Modifier |
Established patient telehealth E/M | 99212–99215 | POS 10 (home) or POS 02 | -95 |
New patient telehealth E/M | 99202–99205 | POS 10 or POS 02 | -95 |
Telephone E/M (audio only) | 99441–99443 | POS 11 | None required |
Online digital E/M (portal) | 99421–99423 | POS 11 | None required |
Remote Patient Monitoring (RPM) and Remote Therapeutic Monitoring (RTM)
CPT Code | Description | Monthly Reimbursement (Est.) |
99453 | RPM device setup and education | ~$19.00 (one-time) |
99454 | RPM device supply and data transmission, per 30 days | ~$55.00 |
99457 | RPM treatment management, first 20 minutes | ~$50.00 |
99458 | RPM treatment management, each additional 20 minutes | ~$41.00 |
98975 | RTM setup (musculoskeletal) | ~$19.00 (one-time) |
98977 | RTM device supply, musculoskeletal, per 30 days | ~$55.00 |
98980 | RTM treatment management, first 20 minutes | ~$50.00 |
98981 | RTM treatment management, each additional 20 minutes | ~$41.00 |
RPM requires at least 16 days of data collection per 30-day period. RTM applies to therapeutic adherence and response monitoring (e.g., exercise adherence, pain scores). Both require initial patient consent and a formal treatment plan.
- Neolytix • Medical Billing
Medical Billing
Chronic Care Management: Untapped Revenue for Rheumatologists
Chronic care management (CCM) codes represent one of the most consistently under-billed revenue opportunities in rheumatology. Patients with RA, SLE, ankylosing spondylitis, or systemic sclerosis almost universally qualify — they have two or more chronic conditions expected to last at least 12 months. Full CCM requirements are published by CMS in the Chronic Care Management fact sheet.
CPT Code | Description | Monthly Reimbursement (Est.) |
99490 | CCM, clinical staff, first 20 min/month | ~$63.00 |
99439 | CCM, each additional 20 min/month | ~$47.00 |
99491 | CCM, physician time, first 30 min/month | ~$85.00 |
99487 | Complex CCM, first 60 min/month | ~$130.00 |
99489 | Complex CCM, each additional 30 min/month | ~$69.00 |
99424 | PCM, physician, first 30 min/month | ~$75.00 |
99425 | PCM, physician, each additional 30 min/month | ~$50.00 |
99426 | PCM, clinical staff, first 20 min/month | ~$60.00 |
99427 | PCM, clinical staff, each additional 20 min/month | ~$44.00 |
Critical Coding Rule: If medication is prescribed or managed during the diagnostic evaluation, CPT 90792 must be used. Billing 90791 when medication services are provided creates significant audit risk. This is one of the most frequently miscoded psychiatry encounters.
Key Requirements for CCM Billing:
- Patient must have 2+ chronic conditions
- Electronic care plan must be in place
- Patient consent must be documented
- 20 minutes of non-face-to-face clinical staff time per calendar month
- Only one practice can bill CCM for a patient per month — position your practice as the managing provider
Revenue Impact (Illustrative Estimate): A rheumatology practice with 300 qualifying chronic patients billing 99490 once monthly generates approximately $18,900/month ($226,800/year) in additional revenue — from care activities that clinical staff are already performing. This is an illustrative estimate based on ~$63/patient/month × 300 patients; actual results vary by payer mix, patient eligibility, and contracted rates.
MIPS & Quality Reporting for Rheumatologists
The Merit-based Incentive Payment System (MIPS) directly affects your Medicare reimbursement rate by up to ±9% in 2026 (based on 2024 performance year). Rheumatologists who fail to report face automatic negative payment adjustments.
Full measure specifications are available in the CMS Quality Payment Program measure library.
Measure # | Description | Data Type |
108 | RA: Disease Activity Assessment | Claims/EHR |
109 | RA: Functional Status Assessment | Claims/EHR |
110 | RA: Tuberculosis Screening Prior to First Biologic | Claims/EHR |
111 | RA: Periodic Assessment of Disease Activity | EHR |
177 | Rheumatoid Arthritis: Glucocorticoid Management | EHR |
374 | Closing the Referral Loop | EHR/Registry |
MIPS Category | 2026 Weight |
Quality | 30% |
Promoting Interoperability | 25% |
Improvement Activities | 15% |
Cost | 30% |
Incident-To Billing & Advanced Practice Provider Rules
Many rheumatology practices employ nurse practitioners (NPs) or physician assistants (PAs). Billing for their services correctly — and compliantly — is critical.
Option 1 — Incident-To Billing (Physician NPI, 100% Reimbursement):
- The physician must have seen the patient for the same condition previously
- The physician must be present in the office suite (not necessarily in the same exam room)
- The APP must be carrying out a physician-established plan of care
- The visit cannot be for a new problem not previously addressed by the physician
Option 2 — Direct APP Billing (APP NPI, 85% Reimbursement):
- The APP bills under their own NPI with physician supervision
- Applies when incident-to conditions are not met (new patient, new problem, physician not on-site)
Compliance Risk: Billing incident-to when the physician is not present in the office suite is a False Claims Act violation. Train front desk staff to flag days when the supervising physician is absent — all APP visits on those days must be billed under the APP’s own NPI.
Common Denial Reasons and How to Fight Back
Denial Code | Reason | Prevention | Appeal Strategy |
CO-50 | Medical necessity not established | Link specific ICD-10 to every procedure | Submit clinical notes documenting necessity |
CO-97 | Procedure not billable separately | Add modifier -25 for same-day E/M | Appeal with documentation of distinct service |
CO-16 | Claim information missing | Audit claim fields pre-submission | Correct and resubmit with complete data |
M51 | Missing or invalid drug J-code/units | Verify J-code and unit billing per dose | Resubmit with correct code and units |
M76 | Missing drug waste modifier | Apply JW or JZ on every drug line | Resubmit with correct modifier |
N519 | Invalid modifier | Validate modifier applicability | Correct modifier and resubmit |
PR-204 | Service not covered by plan | Verify benefits pre-service | Appeal with medical necessity letter |
CO-4 | Procedure code inconsistent with modifier | Review modifier-code pairing | Correct combination and resubmit |
Denial Management Workflow
- Capture denials daily — do not let them age past timely filing windows (typically 90–180 days from denial date)
- Categorize by root cause — coding error, documentation gap, eligibility issue, or payer policy
- Appeal with evidence — clinical notes, published clinical guidelines, LCD/NCD references
- Track appeal outcomes — calculate overturn rate by denial type; use this data to drive upstream prevention
- Set KPI targets — benchmark: <5% denial rate, >95% first-pass payment rate, >80% appeal overturn rate
Audit Readiness: High-Risk Areas for Rheumatology
CMS Recovery Audit Contractors (RACs), Zone Program Integrity Contractors (ZPICs), and commercial payer AI auditing systems are actively targeting rheumatology claims.
Current Audit Hotspots
- Biologic Drug Waste Compliance. Any biologic drug claim without either JW or JZ will be automatically flagged. The JZ modifier is now a standard audit trigger.
- High-Level E/M Upcoding. Claims with 99215 > 30% of E/M volume, or 99215 paired with 99417 > 20% of the time, trigger statistical review. Defense requires airtight MDM or time documentation.
- Modifier -25 Overuse. The OIG has consistently identified modifier -25 misuse. Ensure the E/M note is written as if no procedure were performed that day.
- Incident-To Compliance. Payers are cross-referencing physician scheduling data with incident-to claims. Post-pandemic audits have increased significantly.
- Infusion Overlap Billing. Billing concurrent infusion codes (96368) when only sequential infusions occurred — or billing 96367 when concurrent codes apply — remains a consistent audit target.
Audit-Ready Documentation Checklist
- E/M note includes complete MDM elements: number/complexity of problems, data reviewed, risk of complications
- Time-based coding: total time documented with pre/post-visit activities specified
- Infusion logs: start time, stop time, drug, dose, route, lot number, nursing notes
- JW or JZ modifier on every single-use drug claim
- Modifier -25: E/M note is independently defensible from procedure note
- Incident-to: supervising physician was present in office suite on service date
- Prior authorizations: saved with service date documentation
- MIPS data elements: captured as structured data in EHR
Revenue-Optimized Billing Workflow
Step-by-Step Revenue Cycle
- Pre-Visit (Day Before)
- Verify insurance eligibility and benefits
- Confirm active prior authorization for biologics
- Flag patients with outstanding balances
- At Check-In
- Confirm demographic and insurance data
- Collect copays/coinsurance per benefit verification
- Obtain or confirm CCM consent if enrolled
- During theEncounter
- Capture structured diagnosis codes with laterality and specificity
- Document time if using time-based E/M coding
- Record infusion start/stop times, drug lot numbers
- Coding & Charge Capture (Same Day)
- Apply correct E/M level based on MDM or time
- Link all procedure codes to supporting ICD-10 codes
- Add appropriate modifiers; verify JW/JZ on drug lines
- Claim Scrubbing (Before Submission)
- Run claim through scrubber for edit validation
- Confirm NPI, place of service, date of service accuracy
- Submit electronically within 24–48 hours of visit
- Post-Submission
- Review ERA/EOBs within 72 hours of receipt
- Work denials within 3 business days
- Track outstanding claims at 30, 60, and 90 days
Revenue Performance Benchmarks
Metric | Target |
Days in A/R | < 35 days |
First-pass payment rate | > 95% |
Denial rate | < 5% |
Net collection rate | > 96% |
Cost to collect | < 4% of net revenue |
Real-World Coding Scenarios
Scenario 1: Established RA Patient — Infusion Day
Patient: 58-year-old with seropositive RA on rituximab. Physician reviews labs (CBC, CMP), assesses disease activity (moderate MDM), documents medication tolerance, adjusts pre-medication orders.
Code | Description |
99214-25 | E/M visit, moderate complexity, separately identifiable |
96413 | Rituximab IV infusion, first hour (chemotherapy admin) |
96415 | Each additional hour |
J9312 × 10 (JZ) | Rituximab 1000 mg (10 units × 100 mg), no waste |
M05.79 | Seropositive RA, multiple sites |
Z79.899 | Long-term biologic therapy |
Scenario 2: New Patient with Suspected SLE
Patient: 32-year-old female with polyarthritis, malar rash, and positive ANA. High complexity new patient visit — multiple possible diagnoses, extensive history, labs ordered.
Code | Description |
99205 | New patient, high complexity MDM |
86038 | ANA |
86235 | Anti-dsDNA |
86664 | Complement C3 |
86665 | Complement C4 |
M32.10 | SLE, organ involvement unspecified |
Scenario 3: Established Gout Patient — Knee Injection with E/M
Patient: 67-year-old with acute gout flare, right knee effusion. Physician examines, aspirates and injects right knee with corticosteroid, reviews uric acid labs, adjusts allopurinol.
Code | Description |
99214-25 | E/M, moderate complexity, distinct from procedure |
20611 | Arthrocentesis, major joint with ultrasound guidance |
J3301 × 4 | Triamcinolone 40 mg injection |
M10.361 | Gout, right knee, due to renal impairment |
Quick Reference: Rheumatology Code Cheat Sheet
Category | Code | Description |
Complex new patient E/M | 99205 | High MDM, ~$261 |
Complex established E/M | 99215 | High MDM, ~$178 |
Major joint injection | 20610 | No ultrasound guidance |
Major joint injection, US-guided | 20611 | With imaging |
IV infusion, first hour | 96365 | Non-chemo biologic |
IV infusion (chemo), first hour | 96413 | Rituximab, etc. |
Subcutaneous injection | 96372 | Therapeutic |
RA, seropositive | M05.79 | Multiple sites |
SLE | M32.10 | Unspecified organ |
Gout | M10.9 | Use site-specific where possible |
Long-term drug therapy | Z79.899 | All biologic/DMARD patients |
Separate E/M + procedure | Modifier -25 | Must document independently |
Telehealth visit | Modifier -95 | Synchronous audio/video |
No drug waste | Modifier JZ | Required on all single-use drugs |
Drug waste | Modifier JW | Bill wasted amount separately |
- Neolytix • Contact Us
Schedule a Consultation
Neolytix partners with healthcare organizations across revenue cycle, credentialing, and administrative operations ,14+ years of expertise and AI-enabled automation to reduce inefficiencies and drive sustainable growth.
This guide reflects Neolytix’s expertise in healthcare revenue cycle management and is intended for educational purposes only. It does not constitute legal or compliance advice. CPT codes and reimbursement rates are periodically updated by the AMA and CMS. Always verify current codes and rates using the CMS Physician Fee Schedule Lookup Tool and the AMA CPT code database.
Frequently Asked Questions
What is the difference between CPT 90791 and 90792?
CPT 90791 is used for a psychiatric diagnostic evaluation without medical services. CPT 90792 is used when medical services — including medication prescription or management — are part of the evaluation. Using 90791 when medication is prescribed creates significant audit risk and is one of the most commonly miscoded psychiatry encounters.
How are E&M and psychotherapy billed together in psychiatry?
When both an E&M service and psychotherapy are provided during the same encounter, the E&M code (99202–99215) is billed with a psychotherapy add-on code (90833, 90836, or 90838) based on the duration of psychotherapy. The time spent on psychotherapy cannot be counted toward the E&M level — selecting E&M level based on MDM rather than total time is the safest approach.
What telehealth modifiers are required for psychiatry billing in 2026?
Modifier 95 is used for synchronous video telehealth visits. Modifier 93 is used for audio-only services when the patient lacks video access or declines video. Place of Service 10 applies when the patient is in their home; POS 02 applies for other telehealth locations. All four elements must be correct for the claim to process accurately.
What does the 42 CFR Part 2 update mean for psychiatry billing?
Effective February 16, 2026, 42 CFR Part 2 aligns more closely with HIPAA, allowing a single patient consent to cover treatment, payment, and healthcare operations for Substance Use Disorder records. Practices must update their Notice of Privacy Practices. Missing consent documentation for SUD-related services can create compliance risk and contribute to claim denials.
What are the most common psychiatry billing denials and how can they be prevented?
The most frequent psychiatry denials involve missing exact session time documentation, incorrect use of 90791 vs. 90792, missing or incorrect telehealth modifiers, time overlap between E&M and psychotherapy, and overuse of CPT 90837 without supporting documentation. Documenting exact start and stop times, selecting E&M based on MDM when psychotherapy is also billed, and validating modifiers before submission are the most effective prevention strategies.
Sources & References
- CMS Physician Fee Schedule Look-Up Tool — Centers for Medicare & Medicaid Services
- Federal Register: CY 2026 Medicare Physician Fee Schedule Final Rule — U.S. Federal Register
- CPT Code Overview and Approval Process — American Medical Association
- National Correct Coding Initiative (NCCI) Edits — CMS
- CMS Chronic Pain Management and Treatment (G3002/G3003) Fact Sheet — CMS
- CMS Chronic Care Management FAQ — CMS
- OIG Fraud Prevention & Compliance Resources — Office of Inspector General, HHS
- OIG Report: Modifier 25 Use in Evaluation and Management Services — OIG
- CMS Local Coverage Determinations (LCDs) Database — CMS
- CMS QPP MIPS Quality Measures Library — Quality Payment Program
- CMS 2026 Medicare Telehealth Services List — CMS
- CMS Remote Physiologic Monitoring (RPM) Policy — CMS
- AAPC Certified Professional Coder (CPC) Certification — AAPC
- CMS Medicare Administrative Contractors (MACs) — CMS
